The BluePrint 80-gene molecular subtyping assay enables you to uncover aggressive ER+ Basal tumors to help prevent undertreatment.

Missing ER+ Basal tumors can have serious consequences—these aggressive tumors are likely to recur within the first 3-years, similar to TNBC, and can negatively impact overall survival ¹

• ER percentage score does not reliably identify ER+ Basal subtype tumors – molecular subtyping is required²
• ER+ Basal tumors have significantly worse probability of OS if pCR is not achieved ³
• Patients with ER+ Basal molecular subtype tumor may benefit from neoadjuvant regimens optimized for patients with TNBC/Basal tumors ¹
• These data highlight the importance of using genomic profiling to distinguish ER+ breast cancers that are intrinsically Basal-type since they cannot be identified solely by clinicopathologic features, such as ER expression or grade ¹

Black women have a significantly higher proportion of High Risk HR+/Basal and HR-/Basal tumors compared to White women ⁶

• MammaPrint + BluePrint more precisely stratify tumors resulting in distinct 3- and 10-year outcomes, independent of race, beyond clinical subtype alone ^{4, 5}
•  Black patients with Low Risk, Luminal A-Type tumors had excellent 10-year survival outcomes, similar to outcomes observed in MINDACT, where the patient cohort was predominantly white, suggesting equivalent outcomes among diverse patients when classified by MammaPrint + BluePrint ⁵ 
• MammaPrint and BluePrint subtyping demonstrate equivalent prognostic performance across race. Specifically, females with H2 and Basal-Type tumors had significantly worse outcomes compared to Luminal A-Type tumors, regardless of race ⁶